MedPath

Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet

Phase 3
Recruiting
Conditions
Minor Traumatic Brain Injury
Treatment by Antiplatelet
Registration Number
NCT03780062
Lead Sponsor
Poitiers University Hospital
Brief Summary

All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.

No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
720
Inclusion Criteria
  • Age > 18 Years old
  • Minor traumatic brain injury measured by a Glasgow score between 13 and 15
  • Antiplatelet agent therapy
  • Free subject without tutorship or curatorship
Exclusion Criteria
  • Age < 18 years old
  • Glasgow score <13
  • Traumatic brain injury older than 6 hours
  • Patient without any social security system
  • Patient with renforced protection (tutorship, curatorship, ...)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L3 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

CHU of MONTPELLIER

🇫🇷

Montpellier, France

CHU of NICE

🇫🇷

Nice, France

La Pité Salpêtrière

🇫🇷

Paris, France

CHU of POITIERS

🇫🇷

Poitiers, France

CHU of MONTPELLIER
🇫🇷Montpellier, France
Mustapha SEBBANE, Professor
Contact
0467336733
m-sebbane@chu-montpellier.fr

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.